Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibitionMargaret Kasner, Alexander E. Perl, Neal Flomenberg et al.|Investigational New Drugs|2018Cited by 21
Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR PathwayMargaret Kasner, Alexander E. Perl, Mark A. Weiss et al.|Blood|2012Cited by 3